$AMPH News

Amphastar Pharmaceuticals Unit International Medication Systems Receives FDA Warning Letter Regarding Violations Of Current Good Manufacturing Practice At IMS's Drug Manufacturing Facility In California

B of A Securities Downgrades Amphastar Pharma to Underperform, Lowers Price Target to $20

Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow

Barclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $20

Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty

Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference

Why Wells Fargo Lowered Amphastar Pharmaceuticals, Inc. (AMPH) Price Target to $19

Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower Today

The 5 Most Interesting Analyst Questions From Amphastar Pharmaceuticals’s Q1 Earnings Call

Q1 Earnings Roundup: Amphastar Pharmaceuticals (NASDAQ:AMPH) And The Rest Of The Pharmaceuticals Segment

Amphastar Pharmaceuticals' (NASDAQ:AMPH) Conservative Accounting Might Explain Soft Earnings

Wells Fargo Downgrades Amphastar Pharma to Equal-Weight, Lowers Price Target to $19

Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Piper Sandler Reiterates Neutral on Amphastar Pharma, Lowers Price Target to $21

Earnings Miss: Amphastar Pharmaceuticals, Inc. Missed EPS By 75% And Analysts Are Revising Their Forecasts

Amphastar Pharmaceuticals (AMPH) Is Up 9.4% After Profit Falls Despite New Drug Launches And Licensing Deals

Amphastar Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

Needham Downgrades Amphastar Pharma to Hold